Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

11. Referanser

Al-Batran, S. E., Goetze, T. O., Mueller, D. W., Vogel, A., Winkler, M., Lorenzen, S., . . . Moenig, S. P. (2017). The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer, 17(1), 893. https://doi.org/10.1186/s12885-017-3918-9

Al-Batran, S. E., Hartmann, J. T., Hofheinz, R., Homann, N., Rethwisch, V., Probst, S., . . . Jäger, E. (2008). Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 19(11), 1882-1887. https://doi.org/10.1093/annonc/mdn403

Al-Batran, S. E., Hofheinz, R. D., Pauligk, C., Kopp, H. G., Haag, G. M., Luley, K. B., . . . Tannapfel, A. (2016). Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The Lancet. Oncology, 17(12), 1697-1708. https://doi.org/10.1016/s1470-2045(16)30531-9

Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., . . . Hofheinz, R. D. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London, England), 393(10184), 1948-1957. https://doi.org/10.1016/s0140-6736(18)32557-1

Al-Batran, S. E., Homann, N., Pauligk, C., Illerhaus, G., Martens, U. M., Stoehlmacher, J., . . . Hofheinz, R. D. (2017). Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol, 3(9), 1237-1244. https://doi.org/10.1001/jamaoncol.2017.0515

Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., & Wong, R. (2011). Guidelines for the management of oesophageal and gastric cancer. Gut, 60(11), 1449-1472. https://doi.org/10.1136/gut.2010.228254

Ambiru, S., Miyazaki, M., Ito, H., Nakagawa, K., Shimizu, H., Yoshidome, H., . . . Nakajima, N. (2001). Benefits and limits of hepatic resection for gastric metastases. American journal of surgery, 181(3), 279-283.

Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., . . . Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther, 103(2), 210-216. https://doi.org/10.1002/cpt.911

Ba-Ssalamah, A., Matzek, W., Baroud, S., Bastati, N., Zacherl, J., Schoppmann, S. F., . . . Gore, R. M. (2011). Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results. European radiology, 21(11), 2326-2335. https://doi.org/10.1007/s00330-011-2187-2

Bamias, A., Karina, M., Papakostas, P., Kostopoulos, I., Bobos, M., Vourli, G., . . . Fountzilas, G. (2010). A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer chemotherapy and pharmacology, 65(6), 1009-1021. https://doi.org/10.1007/s00280-010-1256-6

Bang, Y. J., Kim, Y. W., Yang, H. K., Chung, H. C., Park, Y. K., Lee, K. H., . . . Noh, S. H. (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England), 379(9813), 315-321. https://doi.org/10.1016/s0140-6736(11)61873-4

Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., . . . Kang, Y. K. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England), 376(9742), 687-697. https://doi.org/10.1016/s0140-6736(10)61121-x

Barry, J. D., Edwards, P., Lewis, W. G., Dhariwal, D., & Thomas, G. V. (2002). Special interest radiology improves the perceived preoperative stage of gastric cancer. Clinical radiology, 57(11), 984-988.

Best, L. M., Mughal, M., & Gurusamy, K. S. (2016). Laparoscopic versus open gastrectomy for gastric cancer. The Cochrane database of systematic reviews, 3, CD011389. https://doi.org/10.1002/14651858.CD011389.pub2

Bozzetti, F., Bonfanti, G., Bufalino, R., Menotti, V., Persano, S., Andreola, S., . . . Gennari, L. (1982). Adequacy of margins of resection in gastrectomy for cancer. Annals of surgery, 196(6), 685-690.

Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (Eds.). (2017). TNM classification of malignant tumours (8. ed.). Chichester, West Sussex, UK ; Hoboken, NJ: John Wiley & Sons.

Bringeland, E. A., Wasmuth, H. H., Fougner, R., Mjones, P., & Gronbech, J. E. (2014). Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery. The British journal of surgery, 101(13), 1712-1720. https://doi.org/10.1002/bjs.9650

Bringeland, E. A., Wasmuth, H. H., Johnsen, G., Johnsen, T. B., Juel, I. S., Mjones, P., . . . Gronbech, J. E. (2013). Outcomes among patients treated for gastric adenocarcinoma during the last decade. Journal of surgical oncology, 107(7), 752-757. https://doi.org/10.1002/jso.23320

Buckland, G., Travier, N., Huerta, J. M., Bueno-de-Mesquita, H. B., Siersema, P. D., Skeie, G., . . . Gonzalez, C. A. (2015). Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. International journal of cancer, 137(3), 598-606. https://doi.org/10.1002/ijc.29411

Cancer Genome Atlas Research Network. (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513(7517), 202-209. https://doi.org/10.1038/nature13480

Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, Brown University, . . . KU Leuven. (2017). Integrated genomic characterization of oesophageal carcinoma. Nature, 541(7636), 169-175. https://doi.org/10.1038/nature20805

Carmona-Bayonas, A., Jiménez-Fonseca, P., Custodio, A., Sánchez Cánovas, M., Hernández, R., Pericay, C., . . . Gallego, J. (2018). Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 21(1), 96-105. https://doi.org/10.1007/s10120-017-0718-5

Cats, A., Jansen, E. P. M., van Grieken, N. C. T., Sikorska, K., Lind, P., Nordsmark, M., . . . Verheij, M. (2018). Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. The Lancet. Oncology, 19(5), 616-628. https://doi.org/10.1016/s1470-2045(18)30132-3

Choi, Y. Y., Kim, H., Shin, S. J., Kim, H. Y., Lee, J., Yang, H. K., . . . Cheong, J. H. (2019). Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Annals of surgery, 270(2), 309-316. https://doi.org/10.1097/sla.0000000000002803

Chu, M. P., Hecht, J. R., Slamon, D., Wainberg, Z. A., Bang, Y. J., Hoff, P. M., . . . Sawyer, M. B. (2017). Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol, 3(6), 767-773. https://doi.org/10.1001/jamaoncol.2016.3358

Cui, M., Li, Z., Xing, J., Yao, Z., Liu, M., Chen, L., . . . Su, X. (2015). A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer. Medical oncology (Northwood, London, England), 32(10), 241. https://doi.org/10.1007/s12032-015-0680-1

Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., . . . Participants, M. T. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine, 355(1), 11-20. https://doi.org/10.1056/NEJMoa055531

Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., . . . Norman, A. R. (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine, 358(1), 36-46. https://doi.org/10.1056/NEJMoa073149

D'Ugo, D., Biondi, A., Tufo, A., & Persiani, R. (2013). Follow-up: the evidence. Digestive surgery, 30(2), 159-168. https://doi.org/10.1159/000350878

de Boer, W. B., Ee, H., & Kumarasinghe, M. P. (2018). Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype. Am J Surg Pathol, 42(1), 1-8. https://doi.org/10.1097/pas.0000000000000924

den Hoed, C. M., & Kuipers, E. J. (2016). Gastric Cancer: How Can We Reduce the Incidence of this Disease? Current gastroenterology reports, 18(7), 34. https://doi.org/10.1007/s11894-016-0506-0

Diaz-Nieto, R., Orti-Rodriguez, R., & Winslet, M. (2013). Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. The Cochrane database of systematic reviews, (9), CD008415. https://doi.org/10.1002/14651858.CD008415.pub2

Dikken, J. L., Jansen, E. P., Cats, A., Bakker, B., Hartgrink, H. H., Kranenbarg, E. M., . . . Verheij, M. (2010). Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol, 28(14), 2430-2436. https://doi.org/10.1200/jco.2009.26.9654

Dikken, J. L., van Sandick, J. W., Maurits Swellengrebel, H. A., Lind, P. A., Putter, H., Jansen, E. P., . . . Cats, A. (2011). Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer, 11, 329. https://doi.org/10.1186/1471-2407-11-329

Earle, C. C., & Maroun, J. A. (1998). Adjuvant chemotherapy after curative resection for gastric cancer: revisiting a meta-analysis of randomised trials. Proc Am Soc Clin Oncol 1998;17:263a. Proc Am Soc Clin Oncol, 17, 263a.

Enzinger, P. C., Burtness, B., Hollis, D., Niedzwiecki, D., Ilson, D., Benson, A. B., . . . Goldberg, R. M. (2010). CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. Journal of Clinical Oncology, 28(15 suppl), 4006. https://doi.org/10.1200/jco.2010.28.15_suppl.4006

Fitzgerald, R. C., Hardwick, R., Huntsman, D., Carneiro, F., Guilford, P., Blair, V., . . . Caldas, C. (2010). Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of medical genetics, 47(7), 436-444. https://doi.org/10.1136/jmg.2009.074237

Ford, H. E., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., . . . Dunn, J. A. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet. Oncology, 15(1), 78-86. https://doi.org/10.1016/s1470-2045(13)70549-7

Forman, D., & Burley, V. J. (2006). Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best practice & research. Clinical gastroenterology, 20(4), 633-649. https://doi.org/10.1016/j.bpg.2006.04.008

Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208. Last update in FOR-2020-02-04-119 fra 01.03.2020. Retrieved from https://lovdata.no/dokument/SF/forskrift/2000-12-01-1208

Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., . . . Tabernero, J. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England), 383(9911), 31-39. https://doi.org/10.1016/s0140-6736(13)61719-5

Fujitani, K., Yang, H. K., Mizusawa, J., Kim, Y. W., Terashima, M., Han, S. U., . . . Tsujinaka, T. (2016). Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. The Lancet. Oncology, 17(3), 309-318. https://doi.org/10.1016/s1470-2045(15)00553-7

Fukase, K., Kato, M., Kikuchi, S., Inoue, K., Uemura, N., Okamoto, S., . . . Asaka, M. (2008). Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet (London, England), 372(9636), 392-397. https://doi.org/10.1016/s0140-6736(08)61159-9

Gotoda, T., Yanagisawa, A., Sasako, M., Ono, H., Nakanishi, Y., Shimoda, T., & Kato, Y. (2000). Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 3(4), 219-225.

Hallinan, J. (2012). CT volumetry for gastric carcinoma staging. Poster presentert på European Congress of Radiology; Vienna, Austria 1-5 mars

Hallissey, M. T., Jewkes, A. J., Dunn, J. A., Ward, L., & Fielding, J. W. (1993). Resection-line involvement in gastric cancer: a continuing problem. The British journal of surgery, 80(11), 1418-1420.

Halm, E. A., Lee, C., & Chassin, M. R. (2002). Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Annals of internal medicine, 137(6), 511-520.

Haugstvedt, T., Viste, A., Eide, G. E., & Söreide, O. (1989). The survival benefit of resection in patients with advanced stomach cancer: the Norwegian multicenter experience. Norwegian Stomach Cancer Trial. World journal of surgery, 13(5), 617-621; discussion 621-612.

Helsedirektoratet. (2019). Nasjonalt handlingsprogram for palliasjon i kreftomsorgen (IS-2800). Oslo: Helsedirektoratet. Retrieved from https://www.helsedirektoratet.no/retningslinjer/palliasjon-i-kreftomsorgen-handlingsprogram

Helsedirektoratet. (2020). Seneffekter etter kreftbehandling (rev. ed.). Oslo: Helsedirektoratet. Retrieved from https://www.helsedirektoratet.no/rapporter/seneffekter-etter-kreftbehandling/Seneffekter%20etter%20kreftbehandling.pdf/_/attachment/inline/3d984c2a-7926-4d1a-a5f0-06d48fe7c95f:f3e498d059734ff34b013c1c206877e488e95600/Seneffekter%20etter%20kreftbehandling.pdf

Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., . . . Hyodo, I. (2013). Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol, 31(35), 4438-4444. https://doi.org/10.1200/jco.2012.48.5805

Honório, M. X., Suzuki, C., Espin-Garcia, O., Allen, M. J., Ma, L., Almugbel, F. A., . . . Elimova, E. (2020). Asian-ethnicity related differences among patients with metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma. Annals of Oncology, 31(Suppl 4), S841-S873. http://dx.doi.org/10.1016/j.annonc.2020.08.1970

Hu, Y., Huang, C., Sun, Y., Su, X., Cao, H., Hu, J., . . . Li, G. (2016). Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol, 34(12), 1350-1357. https://doi.org/10.1200/jco.2015.63.7215

Ichikura, T., Ogawa, T., Chochi, K., Kawabata, T., Sugasawa, H., & Mochizuki, H. (2003). Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World journal of surgery, 27(3), 330-333. https://doi.org/10.1007/s00268-002-6730-9

Irino, T., Sano, T., Hiki, N., Ohashi, M., Nunobe, S., Kumagai, K., . . . Yamaguchi, T. (2018). Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surgical endoscopy, 32(1), 268-275. https://doi.org/10.1007/s00464-017-5673-z

Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., . . . Ajani, J. A. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London, England), 398(10294), 27-40. https://doi.org/10.1016/s0140-6736(21)00797-2

Janssen, C. W., Jr., Lie, R. T., Maartmann-Moe, H., & Matre, R. (1991). The influence of age on the growth and spread of gastric carcinoma. British journal of cancer, 63(4), 623-625.

Japanese Gastric Cancer Association. (2017). Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 20(1), 1-19. https://doi.org/10.1007/s10120-016-0622-4

Jeurnink, S. M., Steyerberg, E. W., Hof, G., van Eijck, C. H., Kuipers, E. J., & Siersema, P. D. (2007). Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients. Journal of surgical oncology, 96(5), 389-396. https://doi.org/10.1002/jso.20828

Kakeji, Y., Morita, M., & Maehara, Y. (2010). Strategies for treating liver metastasis from gastric cancer. Surgery today, 40(4), 287-294. https://doi.org/10.1007/s00595-009-4152-0

Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., . . . Chen, L. T. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 390(10111), 2461-2471. https://doi.org/10.1016/s0140-6736(17)31827-5

Kawanaka, Y., Kitajima, K., Fukushima, K., Mouri, M., Doi, H., Oshima, T., . . . Hirota, S. (2016). Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. Eur J Radiol, 85(5), 989-995. https://doi.org/10.1016/j.ejrad.2016.03.003

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., . . . Moehler, M. (2021). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. The New England journal of medicine, 384(13), 1191-1203. https://doi.org/10.1056/NEJMoa2032125

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., . . . Moehler, M. (2020). Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. Annals of Oncology, 31(Suppl 4), S1142-S1215. /http://dx.doi.org/10.1016/j.annonc.2020.08.2299

Kelly, S., Harris, K. M., Berry, E., Hutton, J., Roderick, P., Cullingworth, J., . . . Smith, M. A. (2001). A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut, 49(4), 534-539.

Killeen, S. D., O'Sullivan, M. J., Coffey, J. C., Kirwan, W. O., & Redmond, H. P. (2005). Provider volume and outcomes for oncological procedures. The British journal of surgery, 92(4), 389-402. https://doi.org/10.1002/bjs.4954

Kim, D. J., Lee, J. H., & Kim, W. (2014). A comparison of total versus partial omentectomy for advanced gastric cancer in laparoscopic gastrectomy. World J Surg Oncol, 12, 64. https://doi.org/10.1186/1477-7819-12-64

Kim, J. J., Lee, J. H., Jung, H. Y., Lee, G. H., Cho, J. Y., Ryu, C. B., . . . Yoon, Y. B. (2007). EMR for early gastric cancer in Korea: a multicenter retrospective study. Gastrointestinal endoscopy, 66(4), 693-700. https://doi.org/10.1016/j.gie.2007.04.013

Kim, M. M., Rana, V., Janjan, N. A., Das, P., Phan, A. T., Delclos, M. E., . . . Krishnan, S. (2008). Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta oncologica (Stockholm, Sweden), 47(3), 421-427. https://doi.org/10.1080/02841860701621233

Kim, S. T., Cristescu, R., Bass, A. J., Kim, K. M., Odegaard, J. I., Kim, K., . . . Kang, W. K. (2018). Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med, 24(9), 1449-1458. https://doi.org/10.1038/s41591-018-0101-z

Kim, T. H., Park, S. R., Ryu, K. W., Kim, Y. W., Bae, J. M., Lee, J. H., . . . Kim, D. Y. (2012). Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. International journal of radiation oncology, biology, physics, 84(5), e585-592. https://doi.org/10.1016/j.ijrobp.2012.07.2378

Komeda, K., Hayashi, M., Kubo, S., Nagano, H., Nakai, T., Kaibori, M., . . . Uchiyama, K. (2014). High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study. World journal of surgery, 38(10), 2692-2697. https://doi.org/10.1007/s00268-014-2608-x

Kondo, H., Gotoda, T., Ono, H., Oda, I., Yamaguchi, H., Saito, D., & Yoshida, S. (2001). Early gastric cancer: endoscopic mucosal resection. Annali italiani di chirurgia, 72(1), 27-31.

Kong, P., Cai, Q., Geng, Q., Wang, J., Lan, Y., Zhan, Y., & Xu, D. (2014). Vitamin intake reduce the risk of gastric cancer: meta-analysis and systematic review of randomized and observational studies. PLoS ONE [Electronic Resource], 9(12), e116060. https://doi.org/10.1371/journal.pone.0116060

Kurokawa, Y., Doki, Y., Mizusawa, J., Terashima, M., Katai, H., Yoshikawa, T., . . . Sasako, M. (2018). Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol, 3(7), 460-468. https://doi.org/10.1016/s2468-1253(18)30090-6

Kwee, R. M., & Kwee, T. C. (2007). Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol, 25(15), 2107-2116. https://doi.org/10.1200/jco.2006.09.5224

Kwon, H. C., Kim, M. C., Kim, K. H., Jang, J. S., Oh, S. Y., Kim, S. H., . . . Kim, H. J. (2010). Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia-Pacific journal of clinical oncology, 6(4), 278-285. https://doi.org/10.1111/j.1743-7563.2010.01331.x

Lai, K. K., Fang, W. L., Wu, C. W., Huang, K. H., Chen, J. H., Lo, S. S., & Li, A. F. (2011). Surgical impact on gastric cancer with locoregional invasion. World journal of surgery, 35(11), 2479-2484. https://doi.org/10.1007/s00268-011-1246-9

Larsen, I. K. (Ed.). (2016). Cancer in Norway 2015: Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Retrieved from https://www.kreftregisteret.no/globalassets/cancer-in-norway/2015/cin2015-special_issue-web.pdf

Larssen, L., Medhus, A. W., Hjermstad, M. J., Korner, H., Glomsaker, T., Søberg, T., . . . Hauge, T. (2011). Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study. Surgical endoscopy, 25(10), 3162-3169. https://doi.org/10.1007/s00464-011-1680-7

Larsson, S. C., Bergkvist, L., & Wolk, A. (2006). Fruit and vegetable consumption and incidence of gastric cancer: a prospective study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 15(10), 1998-2001. https://doi.org/10.1158/1055-9965.epi-06-0402

Lauren, P. (1965). The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta pathologica et microbiologica Scandinavica, 64, 31-49.

Lee, J. H., Lee, C. M., Son, S. Y., Ahn, S. H., Park, D. J., & Kim, H. H. (2014). Laparoscopic versus open gastrectomy for gastric cancer: long-term oncologic results. Surgery, 155(1), 154-164. https://doi.org/10.1016/j.surg.2013.06.015

Lee, J. Y., Choi, I. J., Cho, S. J., Kim, C. G., Kook, M. C., Lee, J. H., . . . Kim, Y. W. (2012). Routine follow-up biopsies after complete endoscopic resection for early gastric cancer may be unnecessary. Journal of gastric cancer, 12(2), 88-98. https://doi.org/10.5230/jgc.2012.12.2.88

Lee, S. M., Kim, S. H., Lee, J. M., Im, S. A., Bang, Y. J., Kim, W. H., . . . Choi, B. I. (2009). Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdom Imaging, 34(4), 430-440. https://doi.org/10.1007/s00261-008-9420-8

Leong, T., Smithers, B. M., Michael, M., Gebski, V., Boussioutas, A., Miller, D., . . . Wong, R. (2015). TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer, 15, 532. https://doi.org/10.1186/s12885-015-1529-x

Liedman, B., Bosaeus, I., Hugosson, I., & Lundell, L. (1998). Long-term beneficial effects of a gastric reservoir on weight control after total gastrectomy: a study of potential mechanisms. The British journal of surgery, 85(4), 542-547. https://doi.org/10.1046/j.1365-2168.1998.00747.x

Lindahl, A. K., Harbitz, T. B., & Liavåg, I. (1988). The surgical treatment of gastric cancer: a retrospective study with special reference to total gastrectomy. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 14(1), 55-62.

Liu, T. S., Wang, Y., Chen, S. Y., & Sun, Y. H. (2008). An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 34(11), 1208-1216. https://doi.org/10.1016/j.ejso.2008.02.002

Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven) § 2-2 Rett til vurdering. LOV-1999-07-02-63. Last update in LOV-2021-05-07-31 fra 01.07.2021. Retrieved from https://lovdata.no/lov/1999-07-02-63/§2-2

Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., . . . Martenson, J. A. (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. The New England journal of medicine, 345(10), 725-730. https://doi.org/10.1056/NEJMoa010187

Mariette, C., Piessen, G., Briez, N., Gronnier, C., & Triboulet, J. P. (2011). Oesophagogastric junction adenocarcinoma: which therapeutic approach? The Lancet. Oncology, 12(3), 296-305. https://doi.org/10.1016/s1470-2045(10)70125-x

Markar, S. R., Mikhail, S., Malietzis, G., Athanasiou, T., Mariette, C., Sasako, M., & Hanna, G. B. (2016). Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis. Annals of surgery, 263(6), 1092-1101. https://doi.org/10.1097/sla.0000000000001542

Martella, L., Bertozzi, S., Londero, A. P., Steffan, A., De Paoli, P., & Bertola, G. (2015). Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore), 94(31), e1113. https://doi.org/10.1097/md.0000000000001113

Martin, R. C., 2nd, Jaques, D. P., Brennan, M. F., & Karpeh, M. (2002). Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? Journal of the American College of Surgeons, 194(5), 568-577.

Mayne, S. T., Risch, H. A., Dubrow, R., Chow, W. H., Gammon, M. D., Vaughan, T. L., . . . Fraumeni, J. F., Jr. (2001). Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 10(10), 1055-1062.

Meng, Q., Tan, S., Jiang, Y., Han, J., Xi, Q., Zhuang, Q., & Wu, G. (2021). Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial. Clin Nutr, 40(1), 40-46. https://doi.org/10.1016/j.clnu.2020.04.043

Miki, Y., Tokunaga, M., Tanizawa, Y., Bando, E., Kawamura, T., & Terashima, M. (2015). Staging Laparoscopy for Patients with cM0, Type 4, and Large Type 3 Gastric Cancer. World journal of surgery, 39(11), 2742-2747. https://doi.org/10.1007/s00268-015-3144-z

Min, J. S., Jin, S. H., Park, S., Kim, S. B., Bang, H. Y., & Lee, J. I. (2012). Prognosis of curatively resected pT4b gastric cancer with respect to invaded organ type. Annals of surgical oncology, 19(2), 494-501. https://doi.org/10.1245/s10434-011-1987-6

Miyata, M., Yokoyama, Y., Okoyama, N., Joh, T., Seno, K., Sasaki, M., . . . Itoh, M. (2000). What are the appropriate indications for endoscopic mucosal resection for early gastric cancer? Analysis of 256 endoscopically resected lesions. Endoscopy, 32(10), 773-778. https://doi.org/10.1055/s-2000-7712

Mortensen, K., Nilsson, M., Slim, K., Schäfer, M., Mariette, C., Braga, M., . . . Lassen, K. (2014). Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. The British journal of surgery, 101(10), 1209-1229. https://doi.org/10.1002/bjs.9582

Nakajima, T. (2002). Gastric cancer treatment guidelines in Japan. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 5(1), 1-5. https://doi.org/10.1007/s101200200000

Nasjonal helseplan (2007-2010). (2006). (Særtrykk av St.prp. nr. 1 (2006-2007) kapittel 6). Oslo: Helse- og omsorgsdepartementet. Retrieved from http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf

Nasjonale faglige retningslinjer, veiledere og kvalitetsindikatorer. § 12-5 I: Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30. Retrieved from https://lovdata.no/lov/2011-06-24-30/§12-5

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION). (2015-2024). [pågående studie]. (NCT02205047). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02205047

Noh, S. H., Park, S. R., Yang, H. K., Chung, H. C., Chung, I. J., Kim, S. W., . . . Bang, Y. J. (2014). Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet. Oncology, 15(12), 1389-1396. https://doi.org/10.1016/s1470-2045(14)70473-5

Oda, I., Saito, D., Tada, M., Iishi, H., Tanabe, S., Oyama, T., . . . Yoshida, S. (2006). A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 9(4), 262-270. https://doi.org/10.1007/s10120-006-0389-0

Okano, K., Maeba, T., Ishimura, K., Karasawa, Y., Goda, F., Wakabayashi, H., . . . Maeta, H. (2002). Hepatic resection for metastatic tumors from gastric cancer. Annals of surgery, 235(1), 86-91.

Pacelli, F., Cusumano, G., Rosa, F., Marrelli, D., Dicosmo, M., Cipollari, C., . . . Doglietto, G. B. (2013). Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA surgery, 148(4), 353-360. https://doi.org/10.1001/2013.jamasurg.309

Paoletti, X., Oba, K., Burzykowski, T., Michiels, S., Ohashi, Y., Pignon, J. P., . . . Buyse, M. (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama, 303(17), 1729-1737. https://doi.org/10.1001/jama.2010.534

Park, H. S., Lee, J. M., Kim, S. H., Lee, J. Y., Yang, H.-K., Han, J. K., & Choi, B. I. (2010). Three-Dimensional MDCT for Preoperative Local Staging of Gastric Cancer Using Gas and Water Distention Methods: A Retrospective Cohort Study. American Journal of Roentgenology, 195(6), 1316-1323. https://doi.org/10.2214/AJR.10.4320

Park, S. H., Sohn, T. S., Lee, J., Lim, D. H., Hong, M. E., Kim, K. M., . . . Kang, W. K. (2015). Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol, 33(28), 3130-3136. https://doi.org/10.1200/jco.2014.58.3930

Park, S. H., Zang, D. Y., Han, B., Ji, J. H., Kim, T. G., Oh, S. Y., . . . Kang, W. K. (2019). ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). J Clin Oncol, 37(Suppl 15), 4001. 

Reim, D., Loos, M., Vogl, F., Novotny, A., Schuster, T., Langer, R., . . . Schuhmacher, C. (2013). Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol, 31(2), 263-271. https://doi.org/10.1200/jco.2012.44.4315

Retana, A., Silverstein, T., & Wassef, W. (2011). An update in endoscopic management of gastric cancer. Current opinion in gastroenterology, 27(6), 576-582. https://doi.org/10.1097/MOG.0b013e32834b9e5e

Riihimäki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016). Metastatic spread in patients with gastric cancer. Oncotarget, 7(32), 52307-52316. https://doi.org/10.18632/oncotarget.10740

Ronellenfitsch, U., Schwarzbach, M., Hofheinz, R., Kienle, P., Kieser, M., Slanger, T. E., & Jensen, K. (2013). Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. The Cochrane database of systematic reviews, (5), CD008107. https://doi.org/10.1002/14651858.CD008107.pub2

Rudloff, U. (2018). Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. Clin Exp Gastroenterol, 11, 447-459. https://doi.org/10.2147/ceg.S163227

Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., . . . Arai, K. (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. The New England journal of medicine, 357(18), 1810-1820. https://doi.org/10.1056/NEJMoa072252

Sano, T., Sasako, M., Mizusawa, J., Yamamoto, S., Katai, H., Yoshikawa, T., . . . Fujitani, K. (2017). Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Annals of surgery, 265(2), 277-283. https://doi.org/10.1097/sla.0000000000001814

Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., . . . Ohashi, Y. (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29(33), 4387-4393. https://doi.org/10.1200/jco.2011.36.5908

Sato, Y., Yamada, T., Yoshikawa, T., Machida, R., Mizusawa, J., Katayama, H., . . . Terashima, M. (2020). Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC). Jpn J Clin Oncol, 50(11), 1321-1324. https://doi.org/10.1093/jjco/hyaa113

Shah, M. A., Janjigian, Y. Y., Stoller, R., Shibata, S., Kemeny, M., Krishnamurthi, S., . . . Kelsen, D. P. (2015). Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol, 33(33), 3874-3879. https://doi.org/10.1200/jco.2015.60.7465

Shapiro, J., van Lanschot, J. J. B., Hulshof, M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., . . . van der Gaast, A. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet. Oncology, 16(9), 1090-1098. https://doi.org/10.1016/s1470-2045(15)00040-6

Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H. T., Prokharau, A., . . . Tabernero, J. (2018). Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 19(11), 1437-1448. https://doi.org/10.1016/s1470-2045(18)30739-3

Shitara, K., Van Cutsem, E., Bang, Y. J., Fuchs, C., Wyrwicz, L., Lee, K. W., . . . Tabernero, J. (2020). Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol, 6(10), 1571-1580. https://doi.org/10.1001/jamaoncol.2020.3370

Shitara, K., Özgüroğlu, M., Bang, Y. J., Di Bartolomeo, M., Mandalà, M., Ryu, M. H., . . . Fuchs, C. S. (2018). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet (London, England), 392(10142), 123-133. https://doi.org/10.1016/s0140-6736(18)31257-1

Smalley, S. R., Benedetti, J. K., Haller, D. G., Hundahl, S. A., Estes, N. C., Ajani, J. A., . . . Macdonald, J. S. (2012). Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol, 30(19), 2327-2333. https://doi.org/10.1200/jco.2011.36.7136

Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2016). Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 27(suppl 5), v38-v49. https://doi.org/10.1093/annonc/mdw350

Smyth, E. C., Wotherspoon, A., Peckitt, C., Gonzalez, D., Hulkki-Wilson, S., Eltahir, Z., . . . Cunningham, D. (2017). Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol, 3(9), 1197-1203. https://doi.org/10.1001/jamaoncol.2016.6762

Songun, I., Putter, H., Kranenbarg, E. M., Sasako, M., & van de Velde, C. J. (2010). Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet. Oncology, 11(5), 439-449. https://doi.org/10.1016/s1470-2045(10)70070-x

Stiekema, J., Trip, A. K., Jansen, E. P., Boot, H., Cats, A., Ponz, O. B., . . . van Sandick, J. W. (2014). The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Annals of surgical oncology, 21(4), 1107-1114. https://doi.org/10.1245/s10434-013-3397-4

Sumpter, K., Harper-Wynne, C., Cunningham, D., Rao, S., Tebbutt, N., Norman, A. R., . . . Oates, J. (2005). Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British journal of cancer, 92(11), 1976-1983. https://doi.org/10.1038/sj.bjc.6602572

Sun, J., Ilich, A. I., Kim, C. A., Chu, M. P., Wong, G. G., Ghosh, S., . . . Sawyer, M. B. (2016). Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients. Clin Colorectal Cancer, 15(3), 257-263. https://doi.org/10.1016/j.clcc.2015.12.008

Syn, N. L., Wee, I., Shabbir, A., Kim, G., & So, J. B. (2019). Pouch Versus No Pouch Following Total Gastrectomy: Meta-analysis of Randomized and Non-randomized Studies. Annals of surgery, 269(6), 1041-1053. https://doi.org/10.1097/sla.0000000000003082

Søreide, J. A., Greve, O. J., Gudlaugsson, E., & Størset, S. (2016). Hepatoid adenocarcinoma of the stomach--proper identification and treatment remain a challenge. Scandinavian journal of gastroenterology, 51(6), 646-653. https://doi.org/10.3109/00365521.2015.1124286

Tanaka, N., Katai, H., Taniguchi, H., Saka, M., Morita, S., Fukagawa, T., & Gotoda, T. (2010). Trends in characteristics of surgically treated early gastric cancer patients after the introduction of gastric cancer treatment guidelines in Japan. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 13(2), 74-77. https://doi.org/10.1007/s10120-009-0536-5

Ter Veer, E., Creemers, A., de Waal, L., van Oijen, M. G. H., & van Laarhoven, H. W. M. (2018). Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. International journal of cancer, 143(2), 438-448. https://doi.org/10.1002/ijc.31325

Ter Veer, E., Haj Mohammad, N., van Valkenhoef, G., Ngai, L. L., Mali, R. M. A., Anderegg, M. C., . . . van Laarhoven, H. W. M. (2016). The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. Journal of the National Cancer Institute, 108(10). https://doi.org/10.1093/jnci/djw166

Tey, J., Back, M. F., Shakespeare, T. P., Mukherjee, R. K., Lu, J. J., Lee, K. M., . . . Zhu, M. (2007). The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. International journal of radiation oncology, biology, physics, 67(2), 385-388. https://doi.org/10.1016/j.ijrobp.2006.08.070

Townsend, C. M., Beauchamp, R. D., Evers, B. M., & Mattox, K. L. (Eds.). (2017). Sabiston textbook of surgery: the biological basis of modern surgical practice (20. ed.). Philadelphia: Elsevier.

Trip, A. K., Nijkamp, J., van Tinteren, H., Cats, A., Boot, H., Jansen, E. P., & Verheij, M. (2014). IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology, 112(2), 289-294. https://doi.org/10.1016/j.radonc.2014.08.039

Ueda, K., Iwahashi, M., Nakamori, M., Nakamura, M., Naka, T., Ishida, K., . . . Yamaue, H. (2009). Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbeck's archives of surgery, 394(4), 647-653. https://doi.org/10.1007/s00423-008-0311-9

Van Cutsem, E., Boni, C., Tabernero, J., Massuti, B., Middleton, G., Dane, F., . . . Rougier, P. (2015). Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol, 26(1), 149-156. https://doi.org/10.1093/annonc/mdu496

Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., . . . Ajani, J. A. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24(31), 4991-4997. https://doi.org/10.1200/jco.2006.06.8429

van der Post, R. S., Oliveira, C., Guilford, P., & Carneiro, F. (2019). Hereditary gastric cancer: what's new? Update 2013-2018. Fam Cancer, 18(3), 363-367. https://doi.org/10.1007/s10689-019-00127-7

van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., . . . Fitzgerald, R. C. (2015). Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. Journal of medical genetics, 52(6), 361-374. https://doi.org/10.1136/jmedgenet-2015-103094

van Hagen, P., Hulshof, M. C., van Lanschot, J. J., Steyerberg, E. W., van Berge Henegouwen, M. I., Wijnhoven, B. P., . . . van der Gaast, A. (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. The New England journal of medicine, 366(22), 2074-2084. https://doi.org/10.1056/NEJMoa1112088

Viste, A., Eide, G. E., Halvorsen, K., Maartmann-Moe, H., & Søreide, O. (1986). The prognostic value of Lauren's histopathological classification system and ABO blood groups in patients with stomach carcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 12(2), 135-141.

Viste, A., Haùgstvedt, T., Eide, G. E., & Soreide, O. (1988). Postoperative complications and mortality after surgery for gastric cancer. Annals of surgery, 207(1), 7-13.

Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2014). Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(5), 584-591. https://doi.org/10.1016/j.ejso.2013.09.020

Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010). Chemotherapy for advanced gastric cancer. The Cochrane database of systematic reviews, (3), CD004064. https://doi.org/10.1002/14651858.CD004064.pub3

Wasmuth, H. H., Thorsen, G., Nordgård, K., & Gjesdahl, C. (1997). Ventrikkelkreft. Et tiårsmateriale med vekt på tidligkreft. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 931-934.

Wei, W. Z., Yu, J. P., Li, J., Liu, C. S., & Zheng, X. H. (2005). Evaluation of contrast-enhanced helical hydro-CT in staging gastric cancer. World J Gastroenterol, 11(29), 4592-4595.

WHO Classification of Tumours Editorial Board (Ed.). (2019). Digestive System Tumours: WHO Classification of Tumours (5. ed.). Geneva: World Health Organization.

Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., . . . Ohtsu, A. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 15(11), 1224-1235. https://doi.org/10.1016/s1470-2045(14)70420-6

Yasuda, K., Shiraishi, N., Suematsu, T., Yamaguchi, K., Adachi, Y., & Kitano, S. (1999). Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. Cancer, 85(10), 2119-2123.

Ychou, M., Boige, V., Pignon, J. P., Conroy, T., Bouche, O., Lebreton, G., . . . Rougier, P. (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol, 29(13), 1715-1721. https://doi.org/10.1200/jco.2010.33.0597

Yu, C., Yu, R., Zhu, W., Song, Y., & Li, T. (2012). Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. Journal of cancer research and clinical oncology, 138(2), 255-259. https://doi.org/10.1007/s00432-011-1085-y

Yu, W., Choi, G. S., & Chung, H. Y. (2006). Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric

Siste faglige endring: 28. september 2021